PapersPMID:16423108
The efficacy and safety of exogenous melatonin for primary sleep disorders. A meta-analysis.
melatoninWhat moved
1 findingHow to read these marks →- Decreases sleep onset latency
very limitedreplicated ×11
“Melatonin decreased sleep onset latency (weighted mean difference [WMD]: -11.7 minutes; 95% confidence interval [CI]: -18.2, -5.2)); it was decreased to a greater extent in people with delayed sleep phase syndrome (WMD: -38.8 minutes; 95% CI: -50.3, -27.3; n=2) compared with people with insomnia (WMD: -7.2 minutes; 95% CI: -12.0, -2.4; n=12).”
- Study
- meta-analysis
- Effect
- −11.7 mean difference, 95% CI −18.2 to −5.2
- Population
- people with primary sleep disorders (insomnia and delayed sleep phase syndrome pooled); pooled randomised controlled trials
Study record
- Design
- meta-analysis
- Species
- human
- Population
- adults with primary sleep disorders (including delayed sleep phase syndrome and insomnia)
- Participants
- not reported
- Comparator
- not stated in the paper / placebo
- Duration
- 28 days
- Endpoints measured
- 4